Standard BioTools - SLGC Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $4.26
  • Forecasted Upside: 102.86%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.10
▼ -0.1 (-4.55%)
Get New Standard BioTools Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SLGC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SLGC

Analyst Price Target is $4.26
▲ +102.86% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Standard BioTools in the last 3 months. The average price target is $4.26, with a high forecast of $7.00 and a low forecast of $2.30. The average price target represents a 102.86% upside from the last price of $2.10.

This chart shows the closing price for SLGC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 5 contributing investment analysts is to hold stock in Standard BioTools. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/30/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/28/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/25/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/23/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/22/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/5/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$3.50 ➝ $2.30Low
9/25/2023Canaccord Genuity GroupReiterated RatingBuy ➝ Hold$2.50Low
9/25/2023Canaccord Genuity GroupDowngradeBuy ➝ Hold$5.00 ➝ $2.50Low
3/29/2023Canaccord Genuity GroupLower TargetBuy$6.00 ➝ $5.00Low
3/29/2023TD CowenLower TargetOutperform$8.00 ➝ $7.00N/A
3/29/2023Stifel NicolausLower TargetBuy$8.00 ➝ $7.00Low
11/17/2022CowenLower Target$8.00Low
8/16/2022CowenLower Target$11.00 ➝ $9.00Low
8/16/2022CowenLower TargetOutperform$11.00 ➝ $9.00Low
6/23/2022CowenLower TargetOutperform$14.00 ➝ $11.00Low
6/23/2022CowenLower TargetOutperform$14.00 ➝ $11.00Low
5/13/2022Canaccord Genuity GroupLower Target$19.00 ➝ $15.00High
2/1/2022Stifel NicolausInitiated CoverageBuy$12.00High
12/10/2021Jefferies Financial GroupInitiated CoverageBuy$16.00Low
11/23/2021CowenInitiated CoverageOutperform$18.00Medium
(Data available from 2/22/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/27/2023
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/26/2023
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/25/2023
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/25/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/24/2023
  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/24/2023
  • 10 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/22/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Standard BioTools logo
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development. Its SomaScan's biomarker discoveries use in diagnostic applications for various diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal, a laboratory-developed test. It serves pharmaceutical and biotechnology companies, and academic and government research institutions. The company has a collaboration agreement with Illumina Cambridge, Ltd for the development of co-branded NGS-based proteomic distributable kits. The company was founded in 1999 and is headquartered in Boulder, Colorado.
Read More

Today's Range

Now: $2.10
Low: $1.93
High: $2.31

50 Day Range

MA: $2.31
Low: $2.10
High: $2.83

52 Week Range

Now: $2.10
Low: $1.73
High: $3.79

Volume

33,910,700 shs

Average Volume

10,825,875 shs

Market Capitalization

$394.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.64

Frequently Asked Questions

What sell-side analysts currently cover shares of Standard BioTools?

The following Wall Street sell-side analysts have issued research reports on Standard BioTools in the last twelve months: Canaccord Genuity Group Inc., Jefferies Financial Group Inc., Stifel Nicolaus, and TD Cowen.
View the latest analyst ratings for SLGC.

What is the current price target for Standard BioTools?

5 Wall Street analysts have set twelve-month price targets for Standard BioTools in the last year. Their average twelve-month price target is $4.26, suggesting a possible upside of 102.9%. Stifel Nicolaus has the highest price target set, predicting SLGC will reach $7.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $2.30 for Standard BioTools in the next year.
View the latest price targets for SLGC.

What is the current consensus analyst rating for Standard BioTools?

Standard BioTools currently has 3 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SLGC, but not buy more shares or sell existing shares.
View the latest ratings for SLGC.

What other companies compete with Standard BioTools?

Other companies that are similar to Standard BioTools include National Research, TrueBlue, CompoSecure, National CineMedia and OppFi. Learn More about companies similar to Standard BioTools.

How do I contact Standard BioTools' investor relations team?

Standard BioTools' physical mailing address is 667 MADISON AVENUE, NEW YORK NY, 10065. The company's listed phone number is 303-625-9000 and its investor relations email address is [email protected]. The official website for Standard BioTools is ii.cmlifesciencesspac.com. Learn More about contacing Standard BioTools investor relations.